| Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer MJ Piccart-Gebhart, M Procter, B Leyland-Jones, A Goldhirsch, M Untch, ... New England Journal of Medicine 353 (16), 1659-1672, 2005 | 6729 | 2005 |
| Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis P Cortazar, L Zhang, M Untch, K Mehta, JP Costantino, N Wolmark, ... The Lancet 384 (9938), 164-172, 2014 | 4792 | 2014 |
| Lapatinib plus capecitabine for HER2-positive advanced breast cancer CE Geyer, J Forster, D Lindquist, S Chan, CG Romieu, T Pienkowski, ... New England journal of medicine 355 (26), 2733-2743, 2006 | 4351 | 2006 |
| The benefits and harms of breast cancer screening: an independent review MG Marmot, DG Altman, DA Cameron, JA Dewar, SG Thompson, ... British journal of cancer 108 (11), 2205-2240, 2013 | 2923 | 2013 |
| Ribociclib as first-line therapy for HR-positive, advanced breast cancer GN Hortobagyi, SM Stemmer, HA Burris, YS Yap, GS Sonke, ... New England Journal of Medicine 375 (18), 1738-1748, 2016 | 2026 | 2016 |
| 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial I Smith, M Procter, RD Gelber, S Guillaume, A Feyereislova, M Dowsett, ... The lancet 369 (9555), 29-36, 2007 | 1988 | 2007 |
| Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer S Modi, W Jacot, T Yamashita, J Sohn, M Vidal, E Tokunaga, J Tsurutani, ... New England Journal of Medicine 387 (1), 9-20, 2022 | 1844 | 2022 |
| Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA. 17 PE Goss, JN Ingle, S Martino, NJ Robert, HB Muss, MJ Piccart, ... Journal of the National Cancer Institute 97 (17), 1262-1271, 2005 | 1492 | 2005 |
| 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with … MS Aapro, J Bohlius, DA Cameron, L Dal Lago, JP Donnelly, N Kearney, ... European journal of cancer 47 (1), 8-32, 2011 | 1282 | 2011 |
| Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer RK Murthy, S Loi, A Okines, E Paplomata, E Hamilton, SA Hurvitz, NU Lin, ... New England Journal of Medicine 382 (7), 597-609, 2020 | 1235 | 2020 |
| 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial D Cameron, MJ Piccart-Gebhart, RD Gelber, M Procter, A Goldhirsch, ... The Lancet 389 (10075), 1195-1205, 2017 | 1196 | 2017 |
| A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated … D Cameron, M Casey, M Press, D Lindquist, T Pienkowski, CG Romieu, ... Breast cancer research and treatment 112, 533-543, 2008 | 1100 | 2008 |
| Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials B Asselain, W Barlow, J Bartlett, J Bergh, E Bergsten-Nordström, J Bliss, ... The Lancet Oncology 19 (1), 27-39, 2018 | 1028 | 2018 |
| Triple-negative breast cancer: disease entity or title of convenience? L Carey, E Winer, G Viale, D Cameron, L Gianni Nature reviews Clinical oncology 7 (12), 683-692, 2010 | 986 | 2010 |
| Identification of molecular apocrine breast tumours by microarray analysis P Farmer, H Bonnefoi, V Becette, M Tubiana-Hulin, P Fumoleau, ... Breast Cancer Research 7, 1-1, 2005 | 985 | 2005 |
| Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial IH Kunkler, LJ Williams, WJL Jack, DA Cameron, JM Dixon The lancet oncology 16 (3), 266-273, 2015 | 931 | 2015 |
| Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced … GN Hortobagyi, SM Stemmer, HA Burris, YS Yap, GS Sonke, ... Annals of Oncology 29 (7), 1541-1547, 2018 | 875 | 2018 |
| Breast cancer risk genes: association analysis in more than 113,000 women L Dorling, S Carvalho, J Allen, A Gonzalez-Neira, C Luccarini, ... New England Journal of Medicine 384 (5), 428-439, 2021 | 829 | 2021 |
| Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial L Gianni, U Dafni, RD Gelber, E Azambuja, S Muehlbauer, A Goldhirsch, ... The lancet oncology 12 (3), 236-244, 2011 | 826 | 2011 |
| A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer P Farmer, H Bonnefoi, P Anderle, D Cameron, P Wirapati, V Becette, ... Nature medicine 15 (1), 68-74, 2009 | 746 | 2009 |
John BartlettDirector of Transformative Pathology, Ontario Institute for Cancer ResearchPotvrđena adresa e-pošte na oicr.on.ca